(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number
WO 01/96347 A1

(51) International Patent Classification[7]: C07D 910/4, 495/04, 471/04, A61K 31/55 // C07D 491/04, 313/00, 221/00, 495/04, 337/00, 221/00, 471/04, 223/00, 221/00

(21) International Application Number: PCT/US01/18864

(22) International Filing Date: 12 June 2001 (12.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/211,595 15 June 2000 (15.06.2000) US

(71) Applicant *(for all designated States except US)*: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. BOX 4000, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ROBL, Jeffrey, A.** [US/US]; 7 Tulip Drive, Newtown, PA 18940 (US). **CHEN, Bang-Chi** [CN/US]; 28 Marion Drive, Plainsboro, NJ 18940 (US). **SUN, Chong-Qing** [CN/US]; 527 Dutch Neck Road, East Windsor, NJ 08520 (US).

(74) Agents: **RODNEY, Burton** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*


[Continued on next page]

(54) Title: HMG-CoA REDUCTASE INHIBITORS AND METHOD




(1)

(57) Abstract: Compounds of structure (1) are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis and pharmaceutically acceptable salts thereof, wherein X is O or S; Z is (2) or (3); n is O or 1; R_1 and R_2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; and R_3 to R_9 are as defined herein.



(2)



(3)

WO 01/96347 A1

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.